Published On: Wed, Oct 19th, 2016

New Analyst Ratings On LivaNova PLC (NASDAQ:LIVN)


Recently stock market analysts have updated their consensus ratings on shares of LivaNova PLC (NASDAQ:LIVN).

Most recent broker ratings

08/31/2016 – LivaNova PLC had its “hold” rating reiterated by analysts at WBB Securities. They now have a USD 60 price target on the stock.

08/04/2016 – LivaNova PLC had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 70 price target on the stock.

02/29/2016 – LivaNova PLC had its “hold” rating reiterated by analysts at Kepler Cheuvreux. They now have a USD 66 price target on the stock.

12/01/2015 – LivaNova PLC had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 60 price target on the stock.

11/25/2015 – LivaNova PLC had its “hold” rating reiterated by analysts at BTIG Research.

10/21/2015 – Berenberg Bank began new coverage on LivaNova PLC giving the company a “buy” rating. They now have a USD 80 price target on the stock.

LivaNova PLC has a 50 day moving average of 59.64 and a 200 day moving average of 54.39. The stock’s market capitalization is 2.78B, it has a 52-week low of 46.79 and a 52-week high of 68.50.

The share price of the company (NASDAQ:LIVN) was up +0.44% during the last trading session, with a high of 57.20 and the volume of LivaNova PLC shares traded was 178674.

LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing. The CRM business unit develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. CRM offers products, including leads and delivery systems, and information systems. The Neuromodulation business unit designs, develops and markets neuromodulation-based medical devices for the treatment of epilepsy and depression. Through the Neuromodulation business unit, the Company markets its implantable VNS Therapy systems that deliver vagus nerve stimulation therapy for the treatment of epilepsy and depression.